Sugi Predict

Sugi Predict / Compounds / SCHEMBL3673663

SCHEMBL3673663

SCHEMBL3673663

O=Cc1cccc2nc[nH]c12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 4/20 0.40
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ PDPK1 O15530 1/20 0.40
▸ CA12 O43570 1/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ CA9 Q16790 1/20 0.40
▸ TNKS2 Q9H2K2 1/20 0.40
▸ KMT2A Q03164 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ THRB P10828 1/20 0.39
▸ BLM P54132 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ TRIM24 O15164 3/20 0.37
▸ TRIM33 Q9UPN9 3/20 0.37
▸ ERN1 O75460 2/20 0.35
▸ ALDH1A1 P00352 4/20 0.34
▸ HPGD P15428 2/20 0.34
▸ HTT P42858 2/20 0.34
▸ IP6K1 Q92551 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29195098 0.81 PARP1 (0.36) PARP1SMN1; SMN2PDPK1CA12ALOX15
SCHEMBL4537907 0.77 HPGD (0.38) PARP1SMN1; SMN2PDPK1CA12ALOX15
SCHEMBL1374558 0.73 PRKCI (0.44) PARP1SMN1; SMN2PDPK1CA12ALOX15
SCHEMBL29117054 0.73 PARP1 (0.37) PARP1SMN1; SMN2PDPK1CA12ALOX15
SCHEMBL196912 0.73 PARP1 (0.42) PARP1SMN1; SMN2PDPK1CA12ALOX15
SCHEMBL3232202 0.71 PARP1 (0.41) PARP1SMN1; SMN2PDPK1CA12ALOX15
SCHEMBL13058006 0.70 MEN1 (0.44) KMT2AMEN1LMNATHRBBLM
SCHEMBL14001322 0.70 PARP1 (0.45) PARP1SMN1; SMN2TNKS2KMT2AMEN1
SCHEMBL29285163 0.70 PARP1 (0.41) PARP1SMN1; SMN2PDPK1ERN1ALDH1A1
SCHEMBL2339658 0.70 MEN1 (0.47) PARP1KMT2AMEN1TRIM24TRIM33

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4466260-A1 COMPOUNDS AND THEIR USE IN TREATING CANCER Astrazeneca AB (SE) 2024-11-27 — — EP disclosed
WO-2024219864-A1 NOVEL COMPOUND EXHIBITING SETDB1 INHIBITORY ACTIVITY, AND USE THEREOF 주식회사 넷타겟 2024-10-24 — — WO disclosed
CN-117964643-B Pyrrole [2,3-b ] pyridine derivative and preparation method and application thereof 苏州朗睿生物医药有限公司 2024-07-02 — — CN disclosed
CN-117964643-A Pyrrole [2,3-b ] pyridine derivative and preparation method and application thereof 苏州朗睿生物医药有限公司 2024-05-03 — — CN disclosed
CN-117447376-A Siama-1 receptor inhibitors of the bicyclic structure 苏州恩华生物医药科技有限公司 2024-01-26 — — CN disclosed
US-11866431-B2 Bicyclic compounds VIVACE THERAPEUTICS, INC. (US) 2024-01-09 — — US disclosed
CN-114702428-B Siama-1 receptor inhibitors of the bicyclic structure 苏州恩华生物医药科技有限公司 2023-11-28 — — CN disclosed
WO-2023139199-A1 COMPOUNDS AND THEIR USE IN TREATING CANCER ASTRAZENECA AB (SE) 2023-07-27 — — WO disclosed
US-20230061429-A1 BICYCLIC COMPOUNDS VIVACE THERAPEUTICS, INC. 2023-03-02 — — US disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 — — US disclosed
EP-2240485-A1 TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Takeda Pharmaceutical Company Limited (JP) 2010-10-20 — — EP disclosed
EP-2125805-A1 SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY Astex Therapeutics Limited (GB) 2009-12-02 — — EP disclosed
WO-2009093747-A1 TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-07-30 — — WO disclosed
WO-2008075109-A1 SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY ASTEX THERAPEUTICS LIMITED (GB) 2008-06-26 — — WO disclosed
US-7214674-B2 Heterocyclymethylpiperidines and -piperazines possessing affinity at 5ht-1 type receptors GLAXO GROUP LIMITED (GB) 2007-05-08 — — US disclosed
US-20050153974-A1 Heterocyclymethylpiperidines and -piperazines possessing affinity at 5ht-1 type receptors GLAXO GROUP LIMITED (GB) 2005-07-14 — — US disclosed
EP-1480974-A1 HETEROCYCLYLMETHYLPIPERIDINES AND -PIPERAZINES POSSESSING AFFINITY AT 5HT-1 TYPE RECEPTORS GLAXO GROUP LIMITED (GB) 2004-12-01 — — EP disclosed
US-6800645-B1 INHIBIT PRODUCTION OR PHYSIOLOGICAL EFFECTS OF TNF, INHIBIT CYCLIC AMP PHOSPHODIESTERASE AVENTIS PHARMA LIMITED (GB) 2004-10-05 — — US disclosed
WO-2003068771-A1 HETEROCYCLYMETHYLPIPERIDINES AND -PIPERAZINES POSSESSING AFFINITY AT 5HT-1 TYPE RECEPTORS GLAXO GROUP LIMITED (GB) 2003-08-21 — — WO disclosed
US-5852008-A Heteroatom substituted benzoyl derivatives that enhance synaptic response mediated by receptors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1998-12-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11866431-B2 Bicyclic compounds YAP1, MYC, TEAD2 PARP1 360/4885SMN1; SMN2 3367/4885PDPK1 136/4885
US-20230061429-A1 BICYCLIC COMPOUNDS YAP1, MYC, TEAD2 PARP1 360/4885SMN1; SMN2 3367/4885PDPK1 136/4885
US-20050153974-A1 Heterocyclymethylpiperidines and -piperazines possessing affinity at 5ht-1 type receptors HTR1A, HTR1D, HTR2C PARP1 1723/4885SMN1; SMN2 2615/4885PDPK1 1395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback